Zhejiang CONBA Pharmaceutical Co.,Ltd. (600572.SS)
CNY 4.39
(-1.35%)
CNY 4.39
(-1.35%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.88 Billion CNY | 7.84% |
| 2022 | 3.6 Billion CNY | 6.04% |
| 2021 | 3.4 Billion CNY | -13.45% |
| 2020 | 3.92 Billion CNY | -20.1% |
| 2019 | 4.91 Billion CNY | -0.06% |
| 2018 | 4.92 Billion CNY | 37.59% |
| 2017 | 3.57 Billion CNY | -10.74% |
| 2016 | 4 Billion CNY | -19.92% |
| 2015 | 5 Billion CNY | 70.85% |
| 2014 | 2.92 Billion CNY | 57.26% |
| 2013 | 1.86 Billion CNY | -11.23% |
| 2012 | 2.09 Billion CNY | 55.6% |
| 2011 | 1.34 Billion CNY | 80.42% |
| 2010 | 747.33 Million CNY | -4.28% |
| 2009 | 780.76 Million CNY | 20.19% |
| 2008 | 649.6 Million CNY | -6.31% |
| 2007 | 693.32 Million CNY | 10.37% |
| 2006 | 628.19 Million CNY | 12.07% |
| 2005 | 560.55 Million CNY | 34.63% |
| 2004 | 416.36 Million CNY | 21.67% |
| 2003 | 342.21 Million CNY | 30.68% |
| 2002 | 261.87 Million CNY | -1.45% |
| 2001 | 265.74 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 2.99 Billion CNY | -5.39% |
| 2024 Q2 | 3.16 Billion CNY | -17.65% |
| 2024 Q1 | 3.84 Billion CNY | -1.16% |
| 2023 Q1 | 4.17 Billion CNY | 15.76% |
| 2023 Q2 | 4.09 Billion CNY | -1.85% |
| 2023 Q3 | 3.64 Billion CNY | -11.07% |
| 2023 Q4 | 3.88 Billion CNY | 6.72% |
| 2023 FY | 3.88 Billion CNY | 7.84% |
| 2022 Q2 | 3.46 Billion CNY | -7.91% |
| 2022 Q4 | 3.6 Billion CNY | 4.73% |
| 2022 FY | 3.6 Billion CNY | 6.04% |
| 2022 Q1 | 3.76 Billion CNY | 10.72% |
| 2022 Q3 | 3.44 Billion CNY | -0.7% |
| 2021 Q3 | 3.27 Billion CNY | -6.23% |
| 2021 Q2 | 3.48 Billion CNY | 0.09% |
| 2021 Q1 | 3.48 Billion CNY | -11.26% |
| 2021 FY | 3.4 Billion CNY | -13.45% |
| 2021 Q4 | 3.4 Billion CNY | 3.92% |
| 2020 Q4 | 3.92 Billion CNY | -13.31% |
| 2020 Q1 | 5.05 Billion CNY | 2.79% |
| 2020 Q3 | 4.53 Billion CNY | -4.1% |
| 2020 Q2 | 4.72 Billion CNY | -6.49% |
| 2020 FY | 3.92 Billion CNY | -20.1% |
| 2019 Q4 | 4.91 Billion CNY | -3.29% |
| 2019 Q2 | 5.41 Billion CNY | 4.98% |
| 2019 Q1 | 5.15 Billion CNY | 4.77% |
| 2019 FY | 4.91 Billion CNY | -0.06% |
| 2019 Q3 | 5.08 Billion CNY | -6.05% |
| 2018 Q3 | 4.97 Billion CNY | 6.2% |
| 2018 Q4 | 4.92 Billion CNY | -1.12% |
| 2018 Q2 | 4.68 Billion CNY | 35.41% |
| 2018 Q1 | 3.46 Billion CNY | -3.24% |
| 2018 FY | 4.92 Billion CNY | 37.59% |
| 2017 Q1 | 3.72 Billion CNY | -6.94% |
| 2017 FY | 3.57 Billion CNY | -10.74% |
| 2017 Q2 | 3.6 Billion CNY | -3.38% |
| 2017 Q3 | 3.45 Billion CNY | -4.03% |
| 2017 Q4 | 3.57 Billion CNY | 3.45% |
| 2016 FY | 4 Billion CNY | -19.92% |
| 2016 Q2 | 4.14 Billion CNY | -18.61% |
| 2016 Q1 | 5.09 Billion CNY | 1.83% |
| 2016 Q3 | 5.48 Billion CNY | 32.35% |
| 2016 Q4 | 4 Billion CNY | -26.99% |
| 2015 Q2 | 4.51 Billion CNY | 55.02% |
| 2015 Q4 | 5 Billion CNY | 13.02% |
| 2015 Q3 | 4.42 Billion CNY | -1.87% |
| 2015 FY | 5 Billion CNY | 70.85% |
| 2015 Q1 | 2.91 Billion CNY | -0.62% |
| 2014 FY | 2.92 Billion CNY | 57.26% |
| 2014 Q1 | 1.93 Billion CNY | 4.0% |
| 2014 Q2 | 2.85 Billion CNY | 47.31% |
| 2014 Q3 | 2.75 Billion CNY | -3.37% |
| 2014 Q4 | 2.92 Billion CNY | 6.23% |
| 2013 Q4 | 1.86 Billion CNY | 1.94% |
| 2013 FY | 1.86 Billion CNY | -11.23% |
| 2013 Q3 | 1.82 Billion CNY | 0.23% |
| 2013 Q2 | 1.82 Billion CNY | -7.44% |
| 2013 Q1 | 1.96 Billion CNY | -6.15% |
| 2012 Q4 | 2.09 Billion CNY | 20.56% |
| 2012 Q3 | 1.74 Billion CNY | 22.46% |
| 2012 Q2 | 1.42 Billion CNY | 0.71% |
| 2012 FY | 2.09 Billion CNY | 55.6% |
| 2012 Q1 | 1.41 Billion CNY | 4.65% |
| 2011 Q4 | 1.34 Billion CNY | -12.72% |
| 2011 Q1 | 813.53 Million CNY | 8.86% |
| 2011 Q2 | 1.28 Billion CNY | 58.28% |
| 2011 Q3 | 1.54 Billion CNY | 19.98% |
| 2011 FY | 1.34 Billion CNY | 80.42% |
| 2010 Q2 | 829.33 Million CNY | 2.68% |
| 2010 FY | 747.33 Million CNY | -4.28% |
| 2010 Q3 | 788.96 Million CNY | -4.87% |
| 2010 Q1 | 807.67 Million CNY | 3.45% |
| 2010 Q4 | 747.33 Million CNY | -5.28% |
| 2009 Q1 | 656.44 Million CNY | 1.05% |
| 2009 FY | 780.76 Million CNY | 20.19% |
| 2009 Q4 | 780.76 Million CNY | -12.07% |
| 2009 Q3 | 887.89 Million CNY | 34.39% |
| 2009 Q2 | 660.68 Million CNY | 0.65% |
| 2008 Q4 | 649.6 Million CNY | 2.4% |
| 2008 FY | 649.6 Million CNY | -6.31% |
| 2008 Q3 | 634.4 Million CNY | -3.99% |
| 2008 Q2 | 660.75 Million CNY | -4.15% |
| 2008 Q1 | 689.38 Million CNY | -0.57% |
| 2007 Q2 | 662.89 Million CNY | -6.76% |
| 2007 Q3 | 923.03 Million CNY | 39.24% |
| 2007 FY | 693.32 Million CNY | 10.37% |
| 2007 Q4 | 693.32 Million CNY | -24.89% |
| 2007 Q1 | 710.95 Million CNY | 13.17% |
| 2006 Q1 | 579.5 Million CNY | 3.38% |
| 2006 Q3 | 624.22 Million CNY | 9.1% |
| 2006 Q4 | 628.19 Million CNY | 0.64% |
| 2006 FY | 628.19 Million CNY | 12.07% |
| 2006 Q2 | 572.16 Million CNY | -1.27% |
| 2005 FY | 560.55 Million CNY | 34.63% |
| 2005 Q4 | 560.55 Million CNY | 14.71% |
| 2005 Q3 | 488.66 Million CNY | 3.52% |
| 2005 Q1 | 460.12 Million CNY | 10.51% |
| 2005 Q2 | 472.04 Million CNY | 2.59% |
| 2004 Q2 | 446.91 Million CNY | 40.22% |
| 2004 Q1 | 318.71 Million CNY | -6.87% |
| 2004 FY | 416.36 Million CNY | 21.67% |
| 2004 Q4 | 416.36 Million CNY | -2.46% |
| 2004 Q3 | 426.87 Million CNY | -4.48% |
| 2003 Q4 | 342.21 Million CNY | 0.0% |
| 2003 FY | 342.21 Million CNY | 30.68% |
| 2002 FY | 261.87 Million CNY | -1.45% |
| 2001 FY | 265.74 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Jiangsu Hengrui Medicine Co., Ltd. | 2.75 Billion CNY | -41.331% |
| Zhangzhou Pientzehuang Pharmaceutical., Ltd | 3.14 Billion CNY | -23.752% |
| Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. | 887.5 Million CNY | -338.147% |
| Aurora Optoelectronics Co.,Ltd. | 1.09 Billion CNY | -253.572% |
| Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd | 290.34 Million CNY | -1239.325% |
| NanJing Pharmaceutical Company Limited | 20.95 Billion CNY | 81.446% |
| GuangYuYuan Chinese Herbal Medicine Co., Ltd. | 1.12 Billion CNY | -247.026% |
| Tonghua Dongbao Pharmaceutical Co., Ltd. | 527.57 Million CNY | -637.072% |